MétaCan
Menu
← Back to cohort

Abstract 12880: Left Ventricular Mass Predicts Cardiac Reverse Remodeling in Patients With Type 2 Diabetes and Coronary Artery Disease Who Are Treated With Empagliflozin

2022· article· en· W4380794938 on OpenAlexaff
Pankaj Puar, Makoto Hibino, Hwee Teoh, Adrian Quan, Raj Kumar Verma, C. David Mazer, Andrew T. Yan, Kim A. Connelly, Subodh Verma

Bibliographic record

VenueCirculation · 2022
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsSt. Michael's HospitalUniversity of Toronto
Fundersnot available
KeywordsEmpagliflozinMedicineCardiologyInternal medicineType 2 diabetesPlaceboCoronary artery diseaseDiabetes mellitusCohortEndocrinology

Abstract

fetched live from OpenAlex

Introduction: Left ventricular (LV) hypertrophy is associated with an elevated risk for cardiovascular disease and all-cause mortality. The cardiovascular benefits of sodium-glucose cotransporter protein-2 (SGLT2) inhibitors have been attributed, in part, to cardiac reverse remodeling. The EMPA-HEART CardioLink-6 study previously reported that SGLT2 inhibition with empagliflozin for 6 months was associated with a significant reduction in LV mass indexed to body surface area (LVMi). We sought to determine in the same cohort if baseline LVMi influences empagliflozin-associated cardiac reverse remodelling. Methods: A total of 97 patients with type 2 diabetes and coronary artery disease was randomized to empagliflozin (10 mg/d) or matching placebo for 6 months in the EMPA-HEART CardioLink-6 study. This cohort was stratified into those with baseline LVMi <60 g/m 2 and those with LVMI ≥60 g/m 2 . Between-group comparisons were conducted using a linear regression model adjusted for baseline differences in LVMi (ANCOVA) that included an interaction term between baseline LVMi sub-group and treatment. Results: The effect empagliflozin had on the change in LVMi over 6 months was significantly different between patients with a baseline LVMi <60 g/m 2 and those whose LVMi was ≥60 g/m 2 . The adjusted difference between those randomized to empagliflozin and those assigned placebo after multivariable adjustment for baseline characteristics was 0.59 g/m 2 (95% CI: -3.01 g/m 2 , 4.19 g/m 2 , P=0.74) and -7.03 g/m 2 (95% CI: -11.06 g/m 2 , -2.99 g/m 2 , P=0.001) in the LVMi <60 g/m 2 and LVMi ≥60 g/m 2 subgroups, respectively (P interaction =0.0054). No significant association was found between baseline LVMi and 6-month change in LV end systolic volume-indexed (P interaction =0.086), LV end diastolic volume-indexed (P interaction =0.34), or LV ejection fraction (P interaction =0.15). Conclusions: In the EMPA-HEART CardioLink-6 cohort, greater cardiac reverse remodelling benefits were observed with empagliflozin in patients with higher baseline LVMi. Studies with larger cohorts and longer follow-ups are warranted to confirm the impact baseline LV mass has on SGLT2 inhibitor-associated remodelling.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.008
GPT teacher head0.191
Teacher spread0.183 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2022
Admission routes1
Has abstractyes

Explore more

Same venueCirculation→Same topicDiabetes Treatment and Management→French-language works237,207→